We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Veeva (VEEV) Set to Grow on Subscription Revenue Focus
Read MoreHide Full Article
On Jul 4, we issued an updated research report on Pleasanton, CA-based Veeva Systems Inc. (VEEV - Free Report) , a global provider of cloud software and data solutions for the life sciences industry. The company currently carries a Zacks Rank #2 (Buy).
Year to date, Veeva’s shares have recorded an average return of 48.5%, higher than that of the Zacks categorized Internet Software Services industry’s average of 15.4%. The company has a solid track characterized by consecutive earnings beat for the four trailing quarters. Further, the company’s earnings estimates moved north over the past one month. Analysts have revised the Zacks Consensus Estimate for second-quarter fiscal 2018 ending Jun 30, wherein earnings moved upward over the past 30 days, from 36 cents to 43 cents per share, which is a bullish sign.
Veeva’s industry-specific focus gives it a significant leverage, in our view. The company’s knowledge on different components of the life sciences industry is helping it to build targeted products. Notably, product like Veeva OpenData provides customer data to all healthcare professionals (HCP), healthcare organizations (HCO) and affiliations across life sciences’ major markets.
The company has strengthened the recurring part of its revenue mix with significant growth in subscription revenues in the reported quarter. Moreover, launches at the Veeva Vault and the Veeva Coomercial Cloud platforms are encouraging. The company is also supported by considerable strength in its CRM platform.
After reporting impressive first-quarter fiscal 2018 results (ending Mar 30), Veeva Systems is optimistic about its pipeline that includes an exclusive range of products on its flagship Vault and Commercial cloud platforms. These products include Vault CTMS, Vault PromoMats Dam, CRM Engage Meeting and CRM Engage Webinar.
A glimpse at the fiscal first-quarter results reveals strong revenues and adjusted earnings. The top and the bottom line beat the Zacks Consensus Estimate. Additionally, solid year-over-year subscription revenue growth has enhanced the recurring part of Veeva Systems’ revenue mix.
Inogen has a long-term expected earnings growth rate of 17.50%. Notably, the stock represents an impressive one-year return of 100%.
Mesa Laboratories has an average positive earnings surprise of 2.84% for the trailing four quarters. Notably, the stock represents an impressive one-year return of 16.7%.
Edap Tms represents an impressive one-year return of 2.2% for the last three months. The company provided a solid earnings surprise of 533.3% in the last reported quarter.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively. And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation. See Them Free>>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Veeva (VEEV) Set to Grow on Subscription Revenue Focus
On Jul 4, we issued an updated research report on Pleasanton, CA-based Veeva Systems Inc. (VEEV - Free Report) , a global provider of cloud software and data solutions for the life sciences industry. The company currently carries a Zacks Rank #2 (Buy).
Year to date, Veeva’s shares have recorded an average return of 48.5%, higher than that of the Zacks categorized Internet Software Services industry’s average of 15.4%. The company has a solid track characterized by consecutive earnings beat for the four trailing quarters. Further, the company’s earnings estimates moved north over the past one month. Analysts have revised the Zacks Consensus Estimate for second-quarter fiscal 2018 ending Jun 30, wherein earnings moved upward over the past 30 days, from 36 cents to 43 cents per share, which is a bullish sign.
Veeva’s industry-specific focus gives it a significant leverage, in our view. The company’s knowledge on different components of the life sciences industry is helping it to build targeted products. Notably, product like Veeva OpenData provides customer data to all healthcare professionals (HCP), healthcare organizations (HCO) and affiliations across life sciences’ major markets.
The company has strengthened the recurring part of its revenue mix with significant growth in subscription revenues in the reported quarter. Moreover, launches at the Veeva Vault and the Veeva Coomercial Cloud platforms are encouraging. The company is also supported by considerable strength in its CRM platform.
After reporting impressive first-quarter fiscal 2018 results (ending Mar 30), Veeva Systems is optimistic about its pipeline that includes an exclusive range of products on its flagship Vault and Commercial cloud platforms. These products include Vault CTMS, Vault PromoMats Dam, CRM Engage Meeting and CRM Engage Webinar.
A glimpse at the fiscal first-quarter results reveals strong revenues and adjusted earnings. The top and the bottom line beat the Zacks Consensus Estimate. Additionally, solid year-over-year subscription revenue growth has enhanced the recurring part of Veeva Systems’ revenue mix.
Stocks to Consider
Other top-ranked stocks in the broader sector include Inogen Inc. (INGN - Free Report) , Mesa Laboratories, Inc. (MLAB - Free Report) and Edap Tms S.a. (EDAP - Free Report) . Notably, all the stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Inogen has a long-term expected earnings growth rate of 17.50%. Notably, the stock represents an impressive one-year return of 100%.
Mesa Laboratories has an average positive earnings surprise of 2.84% for the trailing four quarters. Notably, the stock represents an impressive one-year return of 16.7%.
Edap Tms represents an impressive one-year return of 2.2% for the last three months. The company provided a solid earnings surprise of 533.3% in the last reported quarter.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively. And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation. See Them Free>>